

61. (New) A monoclonal antibody according to claim 60 that modulates the biological function of a Toso protein.

62. (New) A monoclonal antibody according to claim 61 that reduces or eliminates the biological function of a Toso protein.

SUB 61)

63. (New) A monoclonal antibody according to claim 61 that increases the biological function of a Toso protein.

11  
Out

64. (New) An antibody according to claim 59 directed against the extracellular domain of the Toso protein comprising the sequence of amino acid residues 18-253 of figure 2a (SEQ ID NO:2).

65. (New) An antibody according to claim 59 directed against the cytoplasmic domain of the Toso protein comprising the sequence of amino acid residues 273 to 390 of figure 2a (SEQ ID NO:2).

66. (New) A method for treating an apoptosis related condition in a mammal comprising administering an anti-Toso antibody.

**REMARKS UNDER 37 C.F.R. § 1.111**

**Formal Matters**

Claims 58-66 are pending after entry of the amendment above.

All claims pending prior to the filing of this Supplemental Preliminary Amendment are canceled herein without prejudice to renewal.

Support for new claims 58-66 may be found in the claims and specification as originally filed, and particularly in, for example, originally filed claims 22-29 and 34; and specification page 10, lines 19.

Attached hereto is a marked-up version of the changes made to the specification.

The attached page is captioned **"Version with markings to show changes made."**

Applicants respectfully request entry of the amendment.

No new matter has been added.